Oncology Central

US FDA approves larotrectinib, a unique DNA-targeting drug, for NTRK+ cancers

The US FDA have recently approved the first-ever tyrosine receptor kinase inhibitor (TRK) drug to be used in the treatment of tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusion, in cases with no available alternative treatments.It’s only the second time the FDA has approved a cancer drug’s use based on a certain mutation rather than a particular tumor type.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.